Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
3,5-Dicaffeoylquinic acid attenuates poststroke muscle atrophy through GPX4 dependent ferroptosis inhibition.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qi Hu, Zhang Zeyang, Gao Yuanlin, Tian Dan, Peng Qiyue, Zhang Xiongwei, Ou Shanshan, Wang Hao, Zeng Jiuseng, Zhao Aotao, Liu Rong, Yang Ruocong, Zeng Nan
Аннотация
BACKGROUND: Ischemic stroke-induced sarcopenia (ISS) is a major contributor to poststroke motor dysfunction and severely impairs quality of life. Ferroptosis, an iron- and lipid peroxidation- dependent form of programmed cell death, has not been fully explored in ISS.
PURPOSE: To evaluate the natural compound 3,5-dicaffeoylquinic acid (3,5-DCQA) as a novel anti-ferroptosis agent that markedly attenuates ISS via glutathione peroxidase 4 (GPX4)-mediated ferroptosis inhibition.
METHODS: A permanent middle cerebral artery occlusion (pMCAO) rat model was established. Cerebral injury was assessed using laser speckle contrast imaging and Zea-Longa neurological scoring. The effect of 3,5-DCQA on muscle function was evaluated through behavioral analyses and histopathological staining. Molecular interactions were validated by combining GPX4 silencing via siRNA in L6 cells with RNA-seq and surface plasmon resonance (SPR). The involvement of the ferroptosis signaling pathway in ISS was examined using flow cytometry, immunofluorescence (IF), immunohistochemistry (IHC), and Western blotting (WB).
RESULTS: 3,5-DCQA markedly improved muscle mass, strength, and motor performance. Mechanistically, it reduced ferrous iron and lipid peroxidation products, including malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and lipid peroxides, and downregulated muscle atrophy factors, muscle RING-finger protein-1 (MuRF1) and muscle atrophy F-box (MAFbx). In vitro, 3,5-DCQA decreased reactive oxygen species (ROS) and ferrous iron accumulation, inhibited acyl-CoA synthetase long-chain family member 4 (ACSL4), and restored GPX4 signaling and intracellular GSH, thereby alleviating erastin-induced ferroptosis in L6 myoblasts. Molecular docking and molecular dynamics simulations supported a stable interaction between 3,5-DCQA and GPX4, which was further confirmed by SPR with a KD value of 3.92 × 10-⁶ M. Moreover, 3,5-DCQA weakly bound to MuRF1. These findings confirm GPX4 as the key mediator, as GPX4 knockdown abolished its effects on ferroptosis, oxidative stress, and myogenic recovery.
CONCLUSIONS: 3,5-DCQA mitigates poststroke muscle atrophy through GPX4-dependent ferroptosis suppression and redox restoration, supporting its therapeutic potential in ISS.
PURPOSE: To evaluate the natural compound 3,5-dicaffeoylquinic acid (3,5-DCQA) as a novel anti-ferroptosis agent that markedly attenuates ISS via glutathione peroxidase 4 (GPX4)-mediated ferroptosis inhibition.
METHODS: A permanent middle cerebral artery occlusion (pMCAO) rat model was established. Cerebral injury was assessed using laser speckle contrast imaging and Zea-Longa neurological scoring. The effect of 3,5-DCQA on muscle function was evaluated through behavioral analyses and histopathological staining. Molecular interactions were validated by combining GPX4 silencing via siRNA in L6 cells with RNA-seq and surface plasmon resonance (SPR). The involvement of the ferroptosis signaling pathway in ISS was examined using flow cytometry, immunofluorescence (IF), immunohistochemistry (IHC), and Western blotting (WB).
RESULTS: 3,5-DCQA markedly improved muscle mass, strength, and motor performance. Mechanistically, it reduced ferrous iron and lipid peroxidation products, including malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and lipid peroxides, and downregulated muscle atrophy factors, muscle RING-finger protein-1 (MuRF1) and muscle atrophy F-box (MAFbx). In vitro, 3,5-DCQA decreased reactive oxygen species (ROS) and ferrous iron accumulation, inhibited acyl-CoA synthetase long-chain family member 4 (ACSL4), and restored GPX4 signaling and intracellular GSH, thereby alleviating erastin-induced ferroptosis in L6 myoblasts. Molecular docking and molecular dynamics simulations supported a stable interaction between 3,5-DCQA and GPX4, which was further confirmed by SPR with a KD value of 3.92 × 10-⁶ M. Moreover, 3,5-DCQA weakly bound to MuRF1. These findings confirm GPX4 as the key mediator, as GPX4 knockdown abolished its effects on ferroptosis, oxidative stress, and myogenic recovery.
CONCLUSIONS: 3,5-DCQA mitigates poststroke muscle atrophy through GPX4-dependent ferroptosis suppression and redox restoration, supporting its therapeutic potential in ISS.